Basic Information
| LncRNA/CircRNA Name | CDKN2BAS |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | HCC tissues, HCCLM3, SK-Hep-1, HUH7, MHCC97H, and L02 cells |
| Expression Pattern | up-regulated |
| Function Description | CDKN2BAS was remarkably up regulated in metastatic HCC tissues compared with the adjacent non tumor tissues. CDKN2BAS promotes HCC cell growth and migration in vitro and in vivo. Additionally, CDKN2BAS upregulated the expression of Rho GTPase activating protein 18 (ARHGAP18) by sponging microRNA 153 5p (miR 153 5p), and thus promoted HCC cell migration. Besides, CDKN2BAS downregulated the expression of Kr?ppel like factor 13 (KLF13) and activated MEK ERK1/2 signaling, thus reducing apoptosis in HCC cells |
| Pubmed ID | 30510148 |
| Year | 2018 |
| Title | LncRNA CDKN2BAS predicts poor prognosis in patients with hepatocellular carcinoma and promotes metastasis via the miR-153-5p/ARHGAP18 signaling axis |
External Links
| Links for CDKN2BAS | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |